Alessandro Rizzo

10.1k total citations · 11 hit papers
220 papers, 6.5k citations indexed

About

Alessandro Rizzo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Alessandro Rizzo has authored 220 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Oncology, 105 papers in Pulmonary and Respiratory Medicine and 90 papers in Surgery. Recurrent topics in Alessandro Rizzo's work include Cancer Immunotherapy and Biomarkers (68 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (56 papers) and Renal cell carcinoma treatment (33 papers). Alessandro Rizzo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (68 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (56 papers) and Renal cell carcinoma treatment (33 papers). Alessandro Rizzo collaborates with scholars based in Italy, United States and Türkiye. Alessandro Rizzo's co-authors include Giovanni Brandi, Angela Dalia Ricci, Veronica Mollica, Francesco Massari, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Deniz Can Güven, Simona Tavolari and Alessandro Di Federico and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Alessandro Rizzo

211 papers receiving 6.5k citations

Hit Papers

PD-L1, TMB, MSI, and Other Predictors of Response to Immu... 2021 2026 2022 2024 2021 2022 2022 2022 2023 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
    2021 199 citations Alessandro Rizzo, Angela Dalia Ricci et al. Cancers profile →
  2. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
    2022 138 citations Matteo Rosellini, Andrea Marchetti et al. profile →
  3. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
    2022 138 citations Deniz Can Güven, Taha Koray Şahin et al. profile →
  4. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
    2022 123 citations Matteo Santoni, Alessandro Rizzo et al. Critical Reviews in Oncology/Hematology profile →
  5. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
    2023 117 citations Matteo Santoni, Alessandro Rizzo et al. profile →
  6. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
    2023 115 citations Veronica Mollica, Alessandro Rizzo et al. profile →
  7. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis
    2024 111 citations Taha Koray Şahin, Alessandro Rizzo et al. Cancers profile →
  8. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
    2023 107 citations Alessandro Rizzo, Veronica Mollica et al. profile →
  9. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
    2023 104 citations Deniz Can Güven, Alessandro Rizzo et al. profile →
  10. Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis
    2024 65 citations Taha Koray Şahin, Rüveyda Ayasun et al. Cancers profile →
  11. Prognostic significance of the cachexia index (CXI) in patients with cancer: A systematic review and meta-analysis
    2025 19 citations Taha Koray Şahin, Alessandro Rizzo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alessandro Rizzo Italy 57 3.3k 2.6k 2.0k 1.6k 1.3k 220 6.5k
Yuxian Bai China 37 3.2k 1.0× 2.3k 0.9× 1.2k 0.6× 1.5k 0.9× 1.0k 0.8× 187 6.0k
Toshifumi Wakai Japan 44 2.2k 0.7× 2.2k 0.9× 2.6k 1.3× 1.7k 1.1× 768 0.6× 346 6.0k
Hans Prenen Belgium 41 4.0k 1.2× 2.6k 1.0× 1.3k 0.6× 2.6k 1.6× 1.6k 1.3× 207 8.6k
Young Suk Park South Korea 41 4.0k 1.2× 2.3k 0.9× 1.9k 0.9× 1.3k 0.8× 1.1k 0.9× 227 6.3k
Mario Scartozzi Italy 44 3.7k 1.1× 2.1k 0.8× 834 0.4× 1.7k 1.0× 1.5k 1.2× 343 6.4k
Rachna T. Shroff United States 35 4.2k 1.2× 1.9k 0.7× 3.4k 1.7× 1.6k 1.0× 1.4k 1.1× 172 6.4k
Christophe Borg France 39 4.3k 1.3× 1.7k 0.7× 1.1k 0.5× 1.2k 0.7× 876 0.7× 227 6.3k
Kun‐Huei Yeh Taiwan 38 3.4k 1.0× 2.3k 0.9× 1.4k 0.7× 2.2k 1.4× 914 0.7× 258 6.7k
Robert R. McWilliams United States 46 5.9k 1.8× 1.9k 0.7× 1.9k 0.9× 2.4k 1.5× 1.9k 1.5× 206 8.4k
Todd W. Bauer United States 48 4.1k 1.2× 3.0k 1.1× 3.7k 1.8× 1.4k 0.9× 1.1k 0.9× 185 7.1k

Countries citing papers authored by Alessandro Rizzo

Since Specialization
Citations

This map shows the geographic impact of Alessandro Rizzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Rizzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Rizzo more than expected).

Fields of papers citing papers by Alessandro Rizzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Rizzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Rizzo. The network helps show where Alessandro Rizzo may publish in the future.

Co-authorship network of co-authors of Alessandro Rizzo

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Rizzo. A scholar is included among the top collaborators of Alessandro Rizzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Rizzo. Alessandro Rizzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monte, Anne De, Alessandro Rizzo, Simona Tavolari, et al.. (2025). Molecular Alterations and Pathways in Intrahepatic Cholangiocarcinoma: Available Evidence and New Perspectives. International Journal of Molecular Sciences. 26(24). 11961–11961.
2.
3.
Monteiro, Fernando Sabino Marques, Andrey Soares, Veronica Mollica, et al.. (2024). Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. 196. 104321–104321. 7 indexed citations
4.
Comes, Maria Colomba, Annarita Fanizzi, Samantha Bove, et al.. (2024). Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers‐Based Model. Cancer Medicine. 13(24). e70482–e70482. 1 indexed citations
5.
Şahin, Taha Koray, Rüveyda Ayasun, Alessandro Rizzo, & Deniz Can Güven. (2024). Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis. Cancers. 16(21). 3689–3689. 65 indexed citations breakdown →
6.
Ricci, Angela Dalia, Alessandro Rizzo, Rosalba D’Alessandro, et al.. (2024). Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications. Cancers. 16(20). 3542–3542. 4 indexed citations
7.
Rizzo, Alessandro, L. Rinaldi, Raffaella Massafra, et al.. (2023). 412P Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes. Annals of Oncology. 34. S356–S356. 1 indexed citations
8.
Casadei‐Gardini, Andrea, Francesco Leone, Giovanni Brandi, et al.. (2023). Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy. Frontiers in Oncology. 13. 1128930–1128930. 1 indexed citations
9.
Franzin, Rossana, Alessandra Stasi, Giuseppe De Palma, et al.. (2023). Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular Vesicles. Cells. 12(12). 1655–1655. 5 indexed citations
10.
Brandi, Giovanni & Alessandro Rizzo. (2022). IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?. International Journal of Molecular Sciences. 23(18). 10869–10869. 10 indexed citations
11.
Marchetti, Andrea, Matteo Rosellini, Elisa Tassinari, et al.. (2022). PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?. Cancers. 14(4). 907–907. 11 indexed citations
12.
Mollica, Veronica, Francesco Massari, Alessandro Rizzo, et al.. (2022). Genomics and Immunomics in the Treatment of Urothelial Carcinoma. Current Oncology. 29(5). 3499–3518. 9 indexed citations
13.
Rizzo, Alessandro, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, & Gennaro Palmiotti. (2022). Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology & Hepatology. 16(4). 333–339. 72 indexed citations
14.
Rizzo, Alessandro, Angela Dalia Ricci, Antonio Cusmai, et al.. (2022). Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology. 29(2). 551–564. 5 indexed citations
15.
Forgia, Daniele La, Francesca Arezzo, Maria Colomba Comes, et al.. (2022). Lean Perspectives in an Organizational Change in a Scientific Direction of an Italian Research Institute: Experience of the Cancer Institute of Bari. International Journal of Environmental Research and Public Health. 20(1). 239–239. 4 indexed citations
16.
Mollica, Veronica, Andrea Marchetti, Matteo Rosellini, et al.. (2021). An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences. 22(24). 13519–13519. 18 indexed citations
17.
Mollica, Veronica, Alessandro Rizzo, Matteo Rosellini, et al.. (2021). Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers. 13(3). 546–546. 37 indexed citations
18.
Aurilio, Gaetano, Matteo Santoni, Francesco Massari, et al.. (2021). Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers. 13(20). 5229–5229. 13 indexed citations
19.
Brandi, Giovanni, Angela Dalia Ricci, Alessandro Rizzo, et al.. (2020). Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?. Cancer Communications. 40(9). 461–464. 46 indexed citations
20.
Massari, Francesco, Veronica Mollica, Alessandro Rizzo, et al.. (2020). Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety. 19(10). 1329–1338. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuxian Bai Breakdown of academic impact, for papers by Toshifumi Wakai Breakdown of academic impact, for papers by Hans Prenen Breakdown of academic impact, for papers by Young Suk Park Breakdown of academic impact, for papers by Mario Scartozzi Breakdown of academic impact, for papers by Rachna T. Shroff Breakdown of academic impact, for papers by Christophe Borg Breakdown of academic impact, for papers by Kun‐Huei Yeh Breakdown of academic impact, for papers by Robert R. McWilliams Breakdown of academic impact, for papers by Todd W. Bauer
Rankless by CCL
2026